KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Published version of a preprint
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those targeting the MAPK pathway. Covalent inhibitors of KRAS p.G12C allele allow for direct and specific inhibition of mutant KRAS in cancer cells. However, as for other targeted therapies, the therapeutic potential of these inhibitors can be impaired by intrinsic resistance mechanisms. Therefore, combination strategies are likely needed to improve efficacy. Experimental Design: To identify strategies to maximally leverage direct KRAS inhibition we defined the response of a panel of NSCLC models bearing the KRAS G12C–activating mutation in vitro and in vivo. We used a second-generation KRAS G12C inhibitor, ARS1620 with improved bioavailability over the first generation. We analyzed KRAS downstream effectors signaling to identify mechanisms underlying differential response. To identify candidate combination strategies, we performed a high-throughput drug screening across 112 drugs in combination with ARS1620. We validated the top hits in vitro and in vivo including patient-derived xenograft models. Results: Response to direct KRAS G12C inhibition was heterogeneous across models. Adaptive resistance mechanisms involving reactivation of MAPK pathway and failure to induce PI3K–AKT pathway inactivation were identified as likely resistance events. We identified several model-specific effective combinations as well as a broad-sensitizing effect of PI3K-AKT–mTOR pathway inhibitors. The G12Ci+PI3Ki combination was effective in vitro and in vivo on models resistant to single-agent ARS1620 including patient-derived xenografts models. Conclusions: Our findings suggest that signaling adaptation can in some instances limit the efficacy of ARS1620 but combination with PI3K inhibitors can overcome this resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“early preclinical studies with KRASG12C inhibitors, such as ARS-1620, have suggested a potential role for adaptive feedback as a mechanism of resistance (7) (15).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [15]
In the citing paper
“which is consistent with prior studies suggesting that PI3K is not universally tied to RAS activity (15,29).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [15]
In the citing paper
“For example, a study by Misale et al, suggested that targeting the PI3K/AKT pathway, which is often activated independently of RAS, may improve the efficacy of KRASG12C inhibitors”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [15]
In the citing paper
“and a study by Molina-Arcas et al suggested targeting IGFR and mTOR (15,52).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [15]
In the citing paper
“These combinations, however, are mostly cytostatic, limiting the potential for clinical benefit.”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [4]
34 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090 · cited 1×
“Thus, the genetic background of these models captures some of the heterogeneity of NSCLCKRAS seen in tumors (17).”
BackgroundSelf-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 2×
“Comparison of GI50 values derived from ARS1620 or trametinib treatments revealed 3 subcategories of models: (1) double sensitive models affected by ARS1620 and trametinib, (2) single sensitive (ARS1620-resistant and MEKi-sensitive) models, where MAPK rebound appears to mediate resistance, and (3) MAPK pathway inhibiti…”
BackgroundGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
Torre, L. A., Siegel, R. L., & Jemal, A. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-24223-1_1 · Cited by 1,903 · cited 1×
“Lung cancer is the leading cause of death by cancer in Western countries (7).”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728 · cited 1×
“Pharmacologic targeting of a driver oncogenic event can yield strong responses and in some cases long lasting remissions (10), but their effectiveness is often limited by primary, adaptive, or secondary resistance.”
BackgroundHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · cited 3×
“Indeed, combining MEK and PI3K inhibition affects viability of many cancer models with diverse MAPK pathway–activating events (21, 28, 29, 33).”
BackgroundMethodTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 1×
“In this study, we make use of ARS1620, a second-generation G12C covalent inhibitor with similar characteristics to the previously reported ARS853, but with higher on-target potency and superior bioavailability (18).”
MethodSelf-citationThe quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052 · cited 1×
“For example, recent studies have revealed the diversity of mechanisms of resistance to tyrosine kinase inhibitors in lung cancer (12, 13).”
Background
Cited by
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
“Furthermore, the nucleotide-bound state of KRASG12C can be shifted toward the GDP-bound state by pharmacologically modulating upstream signaling with RTK inhibitors that increase the activity of KRASG12C inhibitors (7, 22, 24).”
BackgroundKRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527
Self-citationEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
“org have higher efficacy than EGFR inhibition in combination with KRASG12C inhibition in lung cancer (10, 12, 13).”
BackgroundSelf-citation
Metadata
- Authors
- Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., Nangia, V., Greninger, P., Egan, R. K., McClanaghan, J., Stein, G. T., Murchie, E., Zarrinkar, P. P., Janes, M. R., Li, L.-S., Liu, Y., Hata, A. N., & Benes, C. H.
- Affiliations
- Harvard University (US)
- 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
- Wellspring Biosciences (United States) (US)
- Kura Oncology (United States) (US)
- Corresponding author
- Hata, Aaron N.
- Benes, Cyril H.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2019-01-15
- Volume
- 25
- Issue
- 2
- Pages
- 796-807
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2895923466
- Semantic Scholar
- 9166596c6a74e67e0627d215b0c27f74780d105e
- Cited by
- 259
- References
- 39
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 32 · 2023: 33 · 2022: 40 · 2021: 46 · 2020: 33 · 2019: 15
- FWCI
- 17.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society (SU2C-AACRDT17-15)
- Wellcome Trust (102696)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS G12C, non-small cell lung cancer, PI3K inhibition, combination therapy, drug resistance, MAPK pathway reactivation, PI3K/AKT/mTOR pathway, patient-derived xenografts, high-throughput drug screening, KRAS-mutant lung cancer
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Alleles, Animals, Drug Screening Assays, Antitumor, Humans, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Gene Silencing, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-0368
- The paper
- Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., Nangia, V., Greninger, P., Egan, R. K., McClanaghan, J., Stein, G. T., Murchie, E., Zarrinkar, P. P., Janes, M. R., Li, L.-S., . . . Benes, C. H. (2019). KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-0368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.